Glurenorm (Gliquidone)

Glurenorm is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

• As monotherapy in patients who have not achieved glycemic control with diet and exercise alone.
• In combination with other oral antidiabetic agents such as metformin or thiazolidinediones.
• As an adjunct to insulin therapy when additional glucose lowering is needed.
• For patients whose renal function allows sulfonylurea use, under physician supervision.

The safety profile of Glurenorm reflects the typical effects observed with sulfonylurea agents, ranging from mild, frequently reported symptoms to rare but serious adverse events. These events are generally dose‑related and may vary among individuals.

Common

• Low blood sugar (hypoglycemia), especially if meals are missed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient visual disturbances.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as skin rash, itching, or swelling.
• Hematologic abnormalities like leukopenia or thrombocytopenia.

Before initiating Glurenorm, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function, as impairment can increase drug exposure.
• Review history of hypoglycemia or adrenal insufficiency.
• Use caution in elderly patients who may be more sensitive to glucose‑lowering effects.
• Evaluate for concurrent use of other sulfonylureas or insulin to avoid additive hypoglycemia.
• Counsel patients on recognizing and managing signs of low blood sugar.
• Consider pregnancy and lactation status; the safety profile in these populations is not well established.
• Monitor blood glucose regularly after dose adjustments.

Glurenorm may interact with other medicines, altering its glucose‑lowering action or increasing the risk of adverse effects.

Avoid

• Other sulfonylureas or insulin preparations, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliquidone levels.
• MAO‑B inhibitors, which have been reported to potentiate sulfonylurea effects.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, as they may affect glucose tolerance.
• Corticosteroids, which can increase blood glucose and require dose adjustments.
• Antidepressants such as SSRIs, which have occasional reports of affecting glycemic control.